Newsfeeds Archive - Spark Newswire

1 minute read

BriaCell Therapeutics Announces Pricing Of $5M Registered Direct Offering Of 2,402,935 Common Shares And Warrants Of The Company At A Combined Purchase Price Of $2/Share

May 15, 8:16 AM

BriaCell Therapeutics Corp. (NASDAQ:BCTX, BCTXW)))) (TSX:BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, today announced it

BCTX

2 minute read

BriaCell 2024 AACR Preclinical Poster Confirms Strong Anti-Cancer Activity Of Bria-OTS+ And Bria-PROS+ Clinical Candidates For Breast And Prostate Cancer

By Benzinga Newsdesk

April 10, 8:10 AM

Preclinical data shows that BriaCell's Bria-OTS+™ and Bria-PROS+™ effectively induce an anti-cancer immune response via multiple mechanisms including naïve helper and killer T cells, dendritic cells, and

BCTX

1 minute read

FDA
News

BriaCell Highlights Data For Antibody-Drug Conjugate Resistant And Central Nervous System Metastatic Breast Cancer At AACR 2024

By Benzinga Newsdesk

April 9, 8:49 AM

PFS of 4.2 months in Phase 2 ADC resistant patients receiving Bria-IMT™ pivotal Phase 3 formulation is twice that of controls in similar studiesPFS results reinforced by larger number of prior treatments in

BCTX

2 minute read

BriaCell Images Confirm Robust Anti-Tumor Activity In Patient With “Eye-Bulging” Metastatic Breast Cancer

By Benzinga Newsdesk

January 4, 9:46 AM

Significant reduction of metastatic breast cancer tumor behind-the-eye after only 3 cycles Powerful anti-tumor response associated with reduction in proptosis (eye-bulging) and reduced ocular painHeavily

BCTX

2 minute read

BriaCell Reports 71% Central Nervous System Response Rate In Advanced Breast Cancer Patients With Central Nervous System Metastases Support Clinical Efficacy Of Bria-IMT, Alone And In Combination With An Immune Checkpoint Inhibitor

By Benzinga Newsdesk

December 28, 9:58 AM

71% intracranial objective response rate (iORR) in BriaCell patients with Central Nervous System (CNS) metastases support clinical efficacy of Bria-IMT™, alone and in combination with an immune checkpoint

BCTX

1 minute read

BriaCell Therapeutics’ Cancer Drug Shows Preliminary Survival, Clinical Benefit In Pretreated Patients

By Vandana Singh

December 20, 1:37 PM

BriaCell Therapeutics Corp (NASDAQ: BCTX) reported preliminary survival and clinical benefit data in a new subset of advanced breast cancer patients treated with BriaCell's Bria-IMT regimen: patients that have developed resistance to (and failed to respond to)

BCTX

3 minute read

BriaCell Highlights Outstanding Topline Survival And Clinical Benefit Data In Advanced Metastatic Breast Cancer At The 2023 SABCS

By Benzinga Newsdesk

December 6, 10:33 AM

Median overall survival of 13.4 months in patients treated with the Bria-IMT™ combination regimen (vs. 6.7-9.8 months for similar patients reported in the literature*). 32 out of 42 patients treated

BCTX

4 minute read

BriaCell 2023 SABCS Posters Confirm Activation Of Cancer-Fighting Immune Cells And Identify Potential Predictors Of Clinical Benefit

By Benzinga Newsdesk

December 6, 10:08 AM

BriaCell's Bria-IMT™ combination regimen with immune checkpoint inhibitors activated cancer-fighting CD8+ T cells turning "Cold" tumors "Hot" on ImmunoPET imaging Advanced protein array technologies showed

BCTX

4 minute read

BriaCell Reports Unprecedented Anti-Tumor Activity If Its Next Generation Personalized Breast And Prostate Cancer Immunotherapies In Tumor Models At The 2023 SITC Annual Meeting; FDA Greenlights Bria-OTS IND

By Benzinga Newsdesk

November 3, 8:35 AM

BriaCell demonstrates unprecedented broad immune system activation in tumor models by BriaCell's next generation breast and prostate cancer immunotherapiesData supports further development of BriaCell's next generation

BCTX

5 minute read

BriaCell Forms Medical Advisory Board Of Distinguished Breast Cancer Specialists To Advance Its Lead Oncology Candidate

By Benzinga Newsdesk

October 25, 9:16 AM

BCTX